Can a GLP-1 help PCOS?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
A GLP-1 can help the weight and metabolic side of PCOS. The 2023 international guideline says anti-obesity medications including liraglutide and semaglutide could be considered for weight management in adults with PCOS, following general population criteria. For fertility outcomes the same guideline restricts them to research settings, and pregnancy must be avoided while taking one.
GLP-1 receptor agonists are not a PCOS treatment in the way the pill or letrozole are. They are weight and metabolic drugs that can be used in PCOS when the eligibility criteria for weight management are met. The 2023 International Evidence-based Guideline states that anti-obesity medications "including liraglutide, semaglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists and orlistat, could be considered, in addition to active lifestyle intervention, for the management of higher weight in adults with PCOS as per general population guidelines".
What the trials show so far
A 2025 meta-analysis of 13 randomised trials, with 397 women receiving a GLP-1 receptor agonist against 330 on metformin and 68 on placebo, found a reduction in BMI of 1.59 kg/m2 (95% CI 2.07 to 1.10 lower) and a reduction in body weight of 3.57 kg (95% CI 5.15 to 1.99 lower) compared with metformin or placebo. HOMA-IR fell by 0.58 (95% CI 0.98 to 0.19 lower). Total testosterone was not significantly reduced. Nausea, vomiting and dizziness were more common.
Fertility and pregnancy come with conditions
This is the part that gets skipped. The 2023 guideline recommends using anti-obesity agents in PCOS for reproductive outcomes "only in research settings to establish the efficacy and safety". Meanwhile, weight loss and improved insulin sensitivity can restore ovulation in a woman who has not ovulated for years, so an unplanned pregnancy is a genuine possibility on these drugs. Reliable contraception is needed while taking a GLP-1, and the medication is stopped before conception is attempted.
Where it fits in a PCOS plan
A GLP-1 addresses weight, glucose and appetite. It does not by itself treat hirsutism, it does not protect the endometrium, and the trial data so far do not show a reliable fall in total testosterone. If those are your priorities, a GLP-1 is an addition to a plan rather than the plan. Muscle preservation matters here too: protein intake and resistance training belong alongside the drug, not after it.
If you have PCOS and meet standard weight management criteria, a GLP-1 is a reasonable conversation. Ask specifically about contraception, about what happens to the plan if you want to conceive, and about how muscle will be protected during the loss.
The clinical detail
Guideline framing: anti-obesity agents in PCOS follow general population eligibility rather than PCOS-specific criteria, so BMI thresholds and comorbidity requirements are the usual ones. The guideline separates weight management (could be considered) from reproductive outcomes (research settings only), and that separation is deliberate given the absence of adequately powered fertility trials.
The 2025 meta-analysis pooled 13 RCTs and was dominated by liraglutide and exenatide comparisons against metformin, with short durations, so the effect sizes should be read as short-term. No included trial reported live birth. Practical monitoring in PCOS is the same as in the general population: gastrointestinal tolerance, gallbladder symptoms, and a plan for contraception. Compounded semaglutide and tirzepatide are outside FDA approval and are not equivalent products.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- International Evidence-based Guideline for the Assessment and Management of PCOS, 2023 summary. Monash University Centre for Health Research and Implementation
- Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Scientific Reports. DOI 10.1038/s41598-025-99622-4
- Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism. PMID 37580314
- Polycystic ovary syndrome: an update on diagnosis and management (2026). Cleveland Clinic Journal of Medicine
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.